文档介绍：作者:introduction (1) essful protocols to produce late-stage matu-rity erythroid cells have been developed based on both umbilical cord-derived hematopoietic stem cell (HSC) populations and human pluripotent stem cell populations. (2) An HSC source has been used more recently to generate an erythrocyte population that was essfully transfused in a human proof-of-principle study; the transfused cells underwent final maturation in vivo and persisted for approximately 1 month after transfusion .(3)Human pluripotent stem cell-based approaches have not yet reached the clinic but are advanced in terms of quality of final red cell product ?(4) The latter approach benefits from an unlimited quantity of input cell line pared with a requirement for repeated primary sourcing with HSCs. However, the human pluripo-tent stem cell starting cells have a longer and plex path of differentiation and require more process control to reach a final product.?A possible method to e the limited mature lineage yield from primary HSCs would be to increase proliferation of the early-stage progenitors. Including novel biologic mediators, such as Notch ligand Delta1, or chemical mediator approaches, such as inhibition of the aryl hydrocarbon receptor .?Early approaches to these scale-up challenges focused on suspension culture and differentiation of HSCs; this step would need to be addressed regardless of the progenitor source. Agitated bag systems have been essfully applied and, in our laboratories, scaled down stirred tank processing?The latter process sustained cell proliferation beyond densities of 1 ×107cells mL-1Proliferative capacity issues can potentially be addressed through prolonging culture to increase the number of blood cells per input cell.?To address these issues, we used two different HSC populations: directly isolated cord blood CD34+cells and CD34+cells after 7 days of pre-expansion with Delta1 Notch ligand. ?The latter population potentially has production b